 High- versus standard-dose megestrol acetate women advanced breast cancer phase III trial Piedmont Oncology Association seventy-two patients advanced breast cancer oral standard-dose megestrol acetate MA mg/d high-dose MA mg/d patients prior trial tamoxifen therapy metastatic disease adjuvant treatment Pretreatment characteristics similar arms High-dose MA superior complete partial response rate time treatment failure median months survival median months standard-dose therapy differences significant adjustment covariates patients high-dose MA failure standard-dose MA treatment none Weight gain distressing side effect standard-dose high-dose patients lbs major cardiovascular events patients high-dose treatment patients standard doses Other toxicity modest High-dose MA significant improvement secondary endocrine therapy advanced breast cancer patients initial endocrine treatment use regular basis results clinical trials